Drug Type Small molecule drug |
Synonyms Mosapride Citrate, Mosapride citrate dihydrate, Mosapride citrate hydrate (JP17) + [5] |
Target |
Mechanism 5-HT4 receptor agonists(Serotonin 4 (5-HT4) receptor agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date JP (30 Jun 1998), |
Regulation- |
Molecular FormulaC27H37ClFN3O12 |
InChIKeyKVKIQHMTGSGTFO-UHFFFAOYSA-N |
CAS Registry636582-62-2 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D01994 | Mosapride Citrate Hydrate | - |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Gastritis | CN | 31 Aug 2005 | |
Urinary Calculi | CN | 01 Jan 1999 | |
Chronic gastritis | JP | 30 Jun 1998 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Dyspepsia | Phase 3 | KR | 12 Dec 2016 | |
Gastrointestinal dysfunction | Phase 2 | CN | 23 Aug 2024 |
Not Applicable | - | vwphrhmgbi(pqhkiolhrj) = btgfkrduvx lusvbchsmy (kpmnxnrhfn ) View more | Positive | 15 Oct 2023 | |||
Placebo | vwphrhmgbi(pqhkiolhrj) = qeyremdhpv lusvbchsmy (kpmnxnrhfn ) View more |